Open-label pilot study (n=12) of a single oral 25 mg dose of psilocybin for adults with treatment-resistant body dysmorphic disorder with follow-up over 3 months.
Open-label, single-group treatment study of up to 12 adult outpatients with body dysmorphic disorder receiving a single oral 25 mg dose of psilocybin with intensive therapeutic support.
Procedures follow prior psilocybin depression protocols: preparation and support from two therapists including 8–9 hours on dosing day, resting-state fMRI pre- and 1 day post-dose, and safety/clinical assessments at day 1, week 1, and months 1, 2, and 3.
Single oral dose psilocybin 25 mg in a single-group open-label design.
Single oral dose of 25 mg psilocybin administered in the Biological Studies Unit.